A neoantigen vaccine generates antitumour immunity in renal cell carcinoma

This phase I trial tests a neoantigen-targeting PCV in patients with high-risk, fully resected clear cell renal cell carcinoma (RCC; stage III or IV) with or without ipilimumab administered adjacent to the vaccine.